Literature DB >> 23759795

Cerebrotendinous xanthomatosis.

Ingemar Björkhem1.   

Abstract

PURPOSE OF REVIEW: Cerebrotendinous xanthomatosis (CTX) is a rare neurological disease characterized by accumulation of cholesterol and cholestanol in brain and tendons caused by a mutation in the sterol 27-hydroxylase gene (CYP27A1). The mechanism behind the accumulation of cholestanol in the brain was recently clarified and a role of 27-hydroxycholesterol as a regulator of brain cholesterol homeostasis has been established. RECENT
FINDINGS: There is a significant flux of the bile acid precursor 7α-hydroxy-4-cholesten-3-one across the blood-brain barrier in cy27-/- mice with its subsequent conversion into cholestanol. CTX patients with white matter lesions and vacuolation are described. CYP27A1 was identified as a candidate gene for sporadic amyotrophic lateral sclerosis (ALS).
SUMMARY: The mechanism behind accumulation of cholestanol in brain and tendons of patients with CTX has been clarified but it is not known why this accumulation is associated with parallel accumulation of cholesterol and formation of xanthomas. Further studies are needed to understand why some patients with CTX develop white matter lesions in the brain. In view of the fact that CTX can present with upper motor neuronal signs it is interesting that CYP27 has been shown to be a candidate gene for sporadic ALS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23759795     DOI: 10.1097/MOL.0b013e328362df13

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  37 in total

Review 1.  Inherited neuropathies: an update.

Authors:  Anna Sagnelli; Giuseppe Piscosquito; Davide Pareyson
Journal:  J Neurol       Date:  2013-09-24       Impact factor: 4.849

2.  Cytochrome P450 27A1 Deficiency and Regional Differences in Brain Sterol Metabolism Cause Preferential Cholestanol Accumulation in the Cerebellum.

Authors:  Natalia Mast; Kyle W Anderson; Joseph B Lin; Yong Li; Illarion V Turko; Curtis Tatsuoka; Ingemar Bjorkhem; Irina A Pikuleva
Journal:  J Biol Chem       Date:  2017-02-11       Impact factor: 5.157

3.  Evaluation of cholesterol metabolism in cerebrotendinous xanthomatosis.

Authors:  Andrea Mignarri; Alessandro Magni; Marina Del Puppo; Gian Nicola Gallus; Ingemar Björkhem; Antonio Federico; Maria Teresa Dotti
Journal:  J Inherit Metab Dis       Date:  2015-07-08       Impact factor: 4.982

Review 4.  Therapeutic targeting of nuclear receptors, liver X and retinoid X receptors, for Alzheimer's disease.

Authors:  Nicholas F Fitz; Kyong Nyon Nam; Radosveta Koldamova; Iliya Lefterov
Journal:  Br J Pharmacol       Date:  2019-05-11       Impact factor: 8.739

Review 5.  Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Drug Metab Rev       Date:  2018-08       Impact factor: 4.518

Review 6.  Current concepts in the treatment of hereditary ataxias.

Authors:  Pedro Braga Neto; José Luiz Pedroso; Sheng-Han Kuo; C França Marcondes Junior; Hélio Afonso Ghizoni Teive; Orlando Graziani Povoas Barsottini
Journal:  Arq Neuropsiquiatr       Date:  2016-03       Impact factor: 1.420

7.  Clinical and molecular genetic features of cerebrotendinous xanthomatosis patients in Chinese families.

Authors:  Chen Chen; Yue Zhang; Hui Wu; Yi-Min Sun; Ye-Hua Cai; Jian-Jun Wu; Jian Wang; Ling-Yun Gong; Zheng-Tong Ding
Journal:  Metab Brain Dis       Date:  2017-06-17       Impact factor: 3.584

8.  Different phenotypes in identical twins with cerebrotendinous xanthomatosis: case series.

Authors:  Dénes Zádori; László Szpisjak; László Madar; Viktória Evelin Varga; Bernadett Csányi; Krisztina Bencsik; István Balogh; Mariann Harangi; Éva Kereszty; László Vécsei; Péter Klivényi
Journal:  Neurol Sci       Date:  2016-11-25       Impact factor: 3.307

Review 9.  Bile acids are nutrient signaling hormones.

Authors:  Huiping Zhou; Phillip B Hylemon
Journal:  Steroids       Date:  2014-05-10       Impact factor: 2.668

10.  Heterozygous Null LDLR Mutation in a Familial Hypercholesterolemia Patient With an Atypical Presentation Because of Alcohol Abuse.

Authors:  Kamaldeep Panach; Abhimanyu Garg; Zahid Ahmad
Journal:  Circ Cardiovasc Genet       Date:  2017-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.